ArticlePloS one2025
PTPN21 inhibits cell apoptosis of acute lymphoblastic leukemia induced by chemotherapeutic agents via GADD45A and JNK signaling pathway.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL), a hematologic malignancy characterized by the uncontrolled proliferation of immature lymphocytes, often results in unfavorable long-term survival prospects for patients. PTPN21, a protein with established roles in oncogenesis, has been implicated in the pathogenesis of ALL. This study explores the role of PTPN21 in ALL cell apoptosis induced by chemotherapeutic agents. Key findings reveal that elevated PTPN21 levels hinder the apoptosis of ALL cells in response to vincristine (VCR) and daunorubicin (DNR). PTPN21 accomplishes this by inhibiting the GADD45A and JNK signaling pathways, thereby reversing cell cycle arrest in the G2/M phase. Restoring GADD45A reverses the anti-apoptotic effect of PTPN21. These findings suggest that targeting PTPN21 in conjunction with chemotherapy may represent a novel therapeutic strategy for ALL, offering potential implications for improving treatment efficacy and overcoming drug resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.